Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-313 in Healthy Participants
NCT05477095Phase 1Completed
- Sponsor
- Axxium Life Sciences
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UB-313 in migraine (5 arms), sponsored by Axxium Life Sciences. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 44 weeks and Immunogenicity Measured by Serum Anti-CGRP Antibodies at 44 weeks. Started Jul 2022; status: completed.
02
Drugs
UB-313
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05477095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477095.